Dr. Yee on Trials Evaluating Treatment in Lenalidomide-Refractory Multiple Myeloma


Andrew Yee, MD, discusses trials evaluating treatment for patients with lenalidomide-refractory multiple myeloma.

Andrew Yee, MD, assistant professor of medicine, Harvard Medical School, hematologist/oncologist, Center for Multiple Myeloma, Massachusetts General Hospital, discusses trials evaluating treatment for patients with lenalidomide (Revlimid)-refractory multiple myeloma.

In the phase 3 OPTIMISMM trial, the overall response rate was 82.2% with the triplet combination of pomalidomide (Pomalyst), bortezomib (Velcade) and dexamethasone compared with 50.0% with bortezomib/dexamethasone alone in patients with relapsed/refractory multiple myeloma who received 1 to 3 prior lines of therapy, including a lenalidomide-containing regimen.

Additionally, the median progression-free survival was 11.2 months with the triplet versus 7.1 months with the doublet (HR, 0.61; 95% CI, 0.49-0.77; P <.0001).

The results of the OPTIMISMM trial have opened the door for other pomalidomide-containing triplet regimens in this space, concludes Yee.

Related Videos
Kimberly Cannavale, MPH
Laurence Albigès, MD, PhD
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego
Julia Foldi, MD, PhD
Joaquim Bellmunt, MD, PhD